the Relationship Between Allergic Rhinitis and the Risk of Symptom in Patients With Mild COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-10

Study Completion Date

2023-06-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

At present, most studies mainly focussed on severe patients, and there was no comparison of symptom differences between AR patients and healthy people with mild infection to evaluate the symptoms of AR patients during infection and to provide preventive treatment in advance. So this experiment was designed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Influences of Allergic Rhinitis and Allergen Immunotherapy on SARS-CoV-2 Vaccination

NCT05009134

Allergic Rhinitis Allergen Immunotherapy SARS-CoV-2

UNKNOWN

Effect of Qi-tonifying Chinese Herbal Products for Treatment of Allergic Rhinitis

NCT01631032

Allergic Rhinitis

COMPLETED PHASE3

Concomitant Intranasal Antihistamine and Corticosteroid in Stepwise Treatment Strategy for Allergic Rhinitis

NCT05708157

Allergic Rhinitis

UNKNOWN

Prospective Multicenter Observational Study and Promotion of the Application of Focused Ultrasound in Allergic Rhinitis

NCT06272032

Allergic Rhinitis

RECRUITING EARLY_PHASE1

Leukotriene D4 Nasal Provocation Test in Allergic Rhinitis

NCT01963741

Allergic Rhinitis Asthma

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After the end of this large-scale infection, the investigators analyzed the re-diagnosis of patients with allergic rhinitis (AR) at the Otolaryngology Clinic, and found significant differences in symptoms between AR and non-AR patients. AR patients had more serious nasal and pharyngeal symptoms. In previous studies on the correlation between allergic diseases and COVID-19 infection, AR was found to be a protective factor to reduce COVID-19 infection and the risk of severe disease . In contrast, a cohort study in South Korea found that AR worsened COVID-19 infection . These studies mainly focussed on severe patients, and there was no comparison of symptom differences between AR patients and healthy people with mild infection.

Allergy may lead to the overall damage of nasal mucosa due to the mechanical and immune defense function of the virus. Immunotherapy will significantly reduce the number and severity of upper respiratory tract infections (including children's common cold). The investigators hypothesized that AR is more likely to aggravate symptoms after infection, while allergen immunotherapy （AIT） may reduce the risk of symptoms as a protective factor for symptoms after AR virus infection. Therefore, the investigators conducted a retrospective analysis on the risk of symptoms after COVID-19 infection in patients with AR, and compared the difference of symptoms after COVID-19 infection in patients with AIT and non-AIT AR.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Allergic Rhinitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

healthy group (HG)

Participants were grouped according to their basic conditions without any intervention

no intervention

Intervention Type OTHER

It's only observational study. No interventions.

allergen immunotherapy group (AIT)

Participants were grouped according to their basic conditions without any intervention

no intervention

Intervention Type OTHER

It's only observational study. No interventions.

allergic rhinitis group (ARG)

Participants were grouped according to their basic conditions without any intervention

no intervention

Intervention Type OTHER

It's only observational study. No interventions.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

no intervention

It's only observational study. No interventions.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all participants completed at least one antigen or nucleic acid test and the results were positive.
* the diagnoses of AR met the international diagnostic standards for AR. The participants had obvious clinical symptoms and the allergen test was positive.

Exclusion Criteria

* suspected new infected person with symptoms（ no antigen or nucleic acid test and the results were nagetive ）
* Participants requiring ICU admission after COVID-19 infection-

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes